semaglutide prediabetes progression to diabetes step trial Efficacy and safety of once-weekly 2·4 mg versus placebo in people with obesity and (STEP 10): a randomised, double-blind, placebo-controlled, multicentre phase 3 Semaglutide: Review and Place in

[DOI] [PMC free article] [PubMed] [Google Scholar] 124.Cai C, Guo Z, Chang X, et al

The doctor said he was pre-diabetic

This litigation is relatively new

GLP-1-based therapies, such as GLP-1 receptor agonists, glucose-dependent insulinotropic polypeptide (GIP) receptor agonists, and dipeptidyl peptidase 4 (DPP-4) inhibitors, improve glucose control through various mechanisms including increased insulin secretion, slower gastric emptying, and reduced postprandial glucagon and food intake

Current status of glucagon-like peptide-1 receptor agonists in metabolic dysfunction-associated steatotic liver disease: a clinical perspective